59 studies (2 from unattributed sources) on Cagrilintide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Nexaph | 15 | 99.3% | View COA → |
| Shanghai Sigma Audley Ssa | 14 | 98.85% | View COA → |
| Hxnet | 14 | 98.58% | View COA → |
| Wuhan Wansheng Biotechnology | 14 | 98.57% | View COA → |
| GYC | 11 | 99.49% | View COA → |
| Sry Labs | 11 | 99.34% | View COA → |
| Hk Peptides | 8 | 98.75% | View COA → |
| Qingdao Sigma Chemical | 7 | 99.4% | View COA → |
Recent certificates: #14812 (99.908%) · #14477 (89.7%) · #21750 (99.8%) · #14441 (99.04%) · #13492 (99.959%) · #13258 (99.6%)
Manufacturers with published third-party certificates of analysis for Cagrilintide. Open a vendor to see every batch we've verified.
Cagrisema represents a highly potent and promising new therapeutic option for individuals struggling with obesity, offering superior weight loss efficacy and improved metabolic parameters compared to current gold-stan…
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment landscape for obesity, potentially offering a more effective therapeutic option than current monotherapies. Cag…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.
Free, no account — handy when you're working with Cagrilintide.